A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Simple Search

You could also try: recurring (205), regular (522), repeated (483), persistent (171), frequent (145), periodic (27)

Press release: Surgeon says hundreds "suffering unnecessarily" from recurrent urine infections

Description
A leading surgeon has said hundreds of people could be "suffering unnecessarily" from recurrent urine infections as a result of undiagnosed
Url
/AboutTheTrust/Newsandpublications/Latestnews/2018/June-2018/Press-release-Surgeon-says-hundreds-suffering-unnecessarily-from-recurrent-urine-infections.aspx

Finance and Performance Reports 2023-24 Month 6 September 2023

Description
Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose Finance Report 2023-24 Month 6
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2023-Trust-documents/Finance-and-Performance-Reports-2023-24-Month-6-September-2023.pdf

CHINA Protocol v2 4.1.11

Description
REC reference 10/H0501/67 1 The CHildren's INterval Appendicectomy (CHINA) Study A Prospective Randomised Evaluation of Interval Appendicectomy versus Cons
Url
/Media/Southampton-Clinical-Research/Research-protocol/CHINA-Protocol-v2-4.1.11.pdf

Binimetinib-Encorafenib

Description
Chemotherapy Protocol SKIN CANCER Binimetinib-Encorafenib Regimen • Skin – Binimetinib-Encorafenib Indication • Unresectable or
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Skincancer/Binimetinib-Encorafenib.pdf

DH IVIg approved indications full guidance July 2011

Description
DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Reference Title Author Publication Date Target Audience Estates Commissioni
Url
/Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf

Sarah Bailey

Description
Auto Generated Title Congratulations to Sarah, who received the Nurses Award at the ESHRE2017 conference after presenting her research on
Url
/ClinicalResearchinSouthampton/For-researchers/Education-and-training/Careerpathways/Inspirational-career-stories/Sarah-Bailey.aspx

Papers Trust Board - 9 September 2025

Description
Date Time Location Chair Apologies Agenda Trust Board – Open Session 09/09/2025 9:00 - 13:00 Conference Room, Heartbeat Education Centre Jenni Dougl
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2025-Trust-documents/Papers-Trust-Board-9-September-2025.pdf

Papers Trust Board - 29 November 2022

Description
Date Time Location Chair Agenda Trust Board – Open Session 29/11/2022 9:00 - 13:20 Conference Room, Heartbeat/Microsoft Teams Jenni Dou
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Trust-Board-29-November-2022.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological diagnosis of endometrial ca
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Nivolumab_240mg

Description
Chemotherapy Protocol HEAD AND NECK CANCER Nivolumab (240mg-14 days) Regimen • Head and Neck – Nivolumab (240mg-14 days) Indication • Th
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Headandneckcancer/Nivolumab-240mg.pdf
1 to 10 of 179
Previous 1 2 3 4 5 … Next